Notice of Cipher Pharmaceuticals Inc. fiscal 2008 fourth quarter and year end conference call

    - Fourth quarter and year end financial results to be released on
    February 18, 2009 -

    Toronto Stock Exchange Symbol: DND

    MISSISSAUGA, ON, Feb. 9 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND),
will host a conference call on Wednesday, February 18, 2009 at 8:30 a.m. (ET)
to discuss its fiscal 2008 fourth quarter and year end financial results.
Cipher invites all interested parties to participate. You can join the call by
dialing 416-644-3414 or 1-800-733-7571. Please call in 15 minutes prior to the
call to secure a line. You will be put on hold until the conference call
    Larry Andrews, President and CEO, will chair the call. A question and
answer session will follow, at which time the operator will direct
participants as to the correct procedure for submitting questions. A taped
replay of the conference call will be available until Wednesday, February 25,
2009 by calling 416-640-1917 or 1-877-289-8525, reference number 21297225
followed by the number sign.
    A live audio webcast of the conference call will be available through Please connect at least 15 minutes prior to the
conference call to ensure adequate time for any software download that may be
needed to hear the webcast. An archived replay of the webcast will be
available for 365 days.

    About Cipher Pharmaceuticals Inc.

    Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The Company's
lead compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and
Drug Administration and Health Canada in the first quarter of 2006. The
product is being marketed in the United States by Kowa Pharmaceuticals America
under the label Lipofen(R). In addition, Cipher is developing formulations of
the pain reliever tramadol (FDA approvable letter in May 2007) and the acne
treatment isotretinoin (FDA approvable letter in April 2007).
    Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding. For more information, please

For further information:

For further information: Craig Armitage, Investor Relations, The Equicom
Group, (416) 815-0700 ext 278, (416) 815-0080 fax,;
Larry Andrews, President and CEO, Cipher Pharmaceuticals, (905) 602-5840 ext
324, (905) 602-0628 fax,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890